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Background: Optimising post-operative joint function is challenging when treating periarticular soft tissue
sarcoma (STS). Radiotherapy reduces local recurrence rates but periarticular fibrosis may adversely affect joint
function. Neo-adjuvant radiotherapy requires lower doses and smaller treatment volumes and therefore has
potential benefits for the management of periarticular STS, but has previously been shown to be associated with
an increased risk of post-operative wound complications. This study assesses initial outcome and complications
after treatment with neo-adjuvant radiotherapy and surgery for patients with periarticular STS.
Methods: Seventeen patients (mean age 52.5 years) were treated using a standard protocol between January 2009
and June 2012 with three-dimensional conformal neo-adjuvant radiotherapy to a dose of 50 Gy in 25 fractions at a
single centre, followed by limb salvage surgery. Patients were assessed weekly for adverse effects during radiotherapy.
Surgery was planned for 6 weeks following completion of radiotherapy. Patients remain under follow-up with regular
Toronto Extremity Salvage Scores (TESS) performed.
Results: No patients had a significant adverse effect during radiotherapy. Three patients (17.6%) suffered a wound
complication following surgery, all treated conservatively. Magnetic resonance imaging (MRI) demonstrated a reduction in
mean maximal tumour diameter from 7.56 to 5.24 cm (p = 0.017, 11 of 17 patients). Tumour necrosis was measured
between 50% and 100% in 10 of 11 resections where accurate assessment was possible. One patient had further surgery
due to incomplete margins. No patients required post-operative radiotherapy. No local recurrences have occurred after a
mean follow-up of 32 months (range 19 to 59 months). Two patients have developed metastatic disease. Mean TESS
scores for upper and lower limb patients were 98.5 and 85.5, respectively, at latest follow-up.
Conclusions: We have demonstrated improved wound complication rates compared to the existing literature on the use
of neo-adjuvant radiotherapy. This may relate to modification of the technique and patient selection compared to previ-
ous series. Excellent functional outcomes can be obtained with this treatment strategy.
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Soft tissue sarcoma (STS) includes a heterogenous group
of rare tumours which account for approximately 1% of
all adult malignancies in the UK, equivalent to an inci-
dence of 37 cases per million per year [1]. STS are tu-
mours of mesodermal origin and are classified according
to their tissue of origin, the most common types being
myxofibrosarcoma, liposarcoma, and leiomyosarcoma* Correspondence: jjgregory@doctors.org.uk
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unless otherwise stated.[2]. STS are prone to local recurrence despite optimal
treatment, and intermediate or high-grade tumours have
significant metastatic potential [3].
Surgery is the primary treatment modality for STS
with the intention to remove the tumour fully whilst
preserving function. Periarticular tumours, defined as
being related to the metaphysis or epiphysis of a long
bone, pose a particular problem to the surgeon due to
the proximity of an articulation and neurovascular struc-
tures. Maximising functional outcome at these sites is
challenging.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Patients were identified using a database which
provides details of those discussed for suitability for
neo-adjuvant radiotherapy.
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dicated in the treatment of tumours which are high
grade, deep to fascia and >5 cm in largest diameter [4,5].
The use of adjuvant versus neo-adjuvant radiotherapy is
controversial. Adjuvant, or post-operative, radiotherapy
has been demonstrated to achieve similar local control
rates and survival to radical resection [4] by using a rec-
ommended dose of 60 to 66 Gy in 2 Gy fractions [5].
The radiation field covers the estimated tumour bed, a
25 mm circumference for clearance, the surgical inci-
sion, and drain sites. Treating patients with adjuvant
radiotherapy as opposed to neo-adjuvant radiotherapy
has been linked to a higher risk of developing acute
toxic skin effects (68% vs. 36% of patients), as well as
being linked to an increased likelihood of developing
joint stiffness, subcutaneous fibrosis and soft tissue
oedema [6,7].
Neo-adjuvant, or pre-operative, radiotherapy is less
commonly used to treat STS in the UK. The standard
regimen for neo-adjuvant radiotherapy is 50 Gy in 2 Gy
fractions with surgery 6 weeks after completion, hence
reducing the dose required for each patient [8]. Patients
treated with neo-adjuvant radiotherapy have been docu-
mented to have a better long-term functional outcome, a
higher likelihood for negative margins on resection and
a lower risk of developing joint stiffness [6,7,9]. How-
ever, concerns with regard to wound complications re-
main, as studies by O’Sullivan et al. and Cannon et al.
have demonstrated a wound complication rate of 34%
to 35% of those treated with neo-adjuvant radiotherapy
as opposed to 16% to 17% for adjuvant radiotherapy
[6,10]. Currently, neo-adjuvant radiotherapy in STS
management is most commonly used if the size of radi-
ation field for post-operative treatment is likely to be
associated with significant late morbidity or if the
tumour is of borderline operability [7,9,11]. In addition,
neo-adjuvant radiotherapy is advantageous for certain ra-
diosensitive histological subtypes (for example, myxoid
liposarcoma) given the degree of tumour necrosis that can
be achieved [12].
Few studies in the literature assess management strat-
egies for periarticular tumours, and none assess the use
of neo-adjuvant radiotherapy in the treatment of peri-
articular STS. Turcotte et al. (2009), Rudiger et al.
(2007) and Pritsch et al. (2007) describe groups of pa-
tients treated for soft tissue sarcoma involving the pop-
liteal fossa [13-15]. However, patients in these studies
were treated with varying management plans, including
primary amputation in 14% to 28% of patients, with
some patients being treated for secondary disease. Al-
though wound complication rates (17% to 27%) and
local recurrence (5.6% to 10.3%) are documented, it is
difficult to interpret these results in relation to primary
disease only.This study aims to assess the initial results, in particu-
lar wound complications, of patients with periarticular
soft tissue sarcoma treated with neo-adjuvant radiother-
apy. Secondly, we aim to specifically assess the func-
tional outcome of these patients as it would be expected
that their functional outcome for tumours at these sites
would differ from ‘standard’ diaphyseal sarcomas.
Methods
A total of 25 patients were identified using a database
which provides details of those discussed for suitability
for neo-adjuvant radiotherapy for a diagnosed soft tissue
sarcoma of the extremity between January 2009 and June
2012 (Figure 1). A periarticular STS was defined as a
sarcoma in which part of the tumour was superficial to
the joint, that is overlying the epiphysis or metaphysis
of the bone. There were some large tumours in the
study that covered part of the diaphysis in addition to
the metaphysis. Tumours which were only overlying
the diaphysis were excluded.
The rationale for the use of neo-adjuvant radiotherapy
is to reduce the radiotherapy dose and field with the
intention of optimising post-operative function. Neo-
adjuvant radiotherapy was not thought to be appropriate
in patients with very rapidly growing tumours (which
may become inoperable if growth continued through
radiotherapy) if limb salvage was not felt to be possible
or if significant pre-existing skin problems rendered the
risk of post-operative wound complications unaccept-
able. Tumours in the groin and the proximal adductor
compartment were not considered due to the high risk
of wound complications seen with tumours at this site.
Tumours in the distal adductor compartment were con-
sidered for pre-operative radiotherapy. In cases felt not
to be suitable for neo-adjuvant radiotherapy, conven-
tional management was employed utilising surgery and
adjuvant radiotherapy.
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by a single clinician. Details of the patient referral, inves-
tigations, diagnosis and management were collected and
analysed.
All patients were treated with neo-adjuvant three-
dimensional conformal radiotherapy, delivered at a single
centre with a dose of 50 Gy in 25 fractions of 2 Gy over
5 weeks treating the radiologically identified tumour and
peri-tumour oedema seen on pre-operative magnetic res-
onance imaging (MRI) with a margin of 2 to 3 cm. Pa-
tients were assessed weekly by a clinician for adverse
effects. Surgery was scheduled at 6 to 8 weeks after com-
pletion of radiotherapy. Patients were then seen at regular
intervals by both surgeons and oncologists for follow-up.
Wounds were assessed at 2 weeks, 6 weeks and 3 months
post-operatively by the surgeon, with subsequent checks
at 6 and 12 months before moving to annual follow-up.
Cast immobilisation was required for two patients due to
removal of the bone involved in the tumour for a total of
6 weeks, and a cricket pad splint was required for 4 weeks
for a patient who required hamstring reconstruction.
The primary outcome measure was the development of
a wound complication, with secondary outcome measures
of functional outcome, local control and metastasis also
assessed. Wound complications were regarded as minor
(conservative management only of ≤6 weeks duration) and
major (requiring operative debridement or soft tissue re-
construction, or prolonged conservative management).
Statistical testing for differences in tumour size was made
using a two-tailed student t-test with a P-value of <0.05
considered to be indicative of significance.
Results
Seventeen patients (10 males, 7 females) with a mean age
of 52.5 years were treated for periarticular STS between
January 2009 and June 2012. All patients were able to
complete the course of neo-adjuvant radiotherapy without
any significant adverse events. One patient had a delay in
surgical excision by 6 weeks due to excessive local ery-
thema. Fifteen patients underwent primary wound closure
at the time of index surgery, with two patients requiring a
split skin graft (SSG) 7 days after initial surgery to
complete wound closure. Three patients (17.6%) suffered
from a wound complication post-operatively, all of which
were treated conservatively (Table 1). There was no correl-
ation between tumour size and wound complication.Table 1 Three patients (17.6%) suffered from a wound compl
conservatively
Gender Age Diagnosis Site of tumour Co
M 83 Myxofibrosarcoma Right forearm/wrist De
M 54 Myxoid Liposarcoma Left calf/ankle W
F 77 Spindle Cell Sarcoma Left wrist/forearm SuThe initial mean maximal tumour diameter was
8.0 cm on MRI scan prior to radiotherapy. Eleven of 17
patients had a further MRI scan between completion of
radiotherapy and surgical treatment, demonstrating a
significant reduction in mean greatest dimension of
tumour size from 7.56 to 5.24 cm (P = 0.017). This cor-
related well with a mean maximal tumour diameter of
5.75 cm on histology. Necrosis of 50% to 100% was dem-
onstrated in 10 of 11 tumours in which it was possible
to make an accurate assessment (Table 2). Seven tu-
mours showed tumour necrosis of over 90%.
Negative surgical margins were achieved in all but one
patient who histologically was found to have a single
breach of the tumour capsule (Table 1); following multi-
disciplinary team (MDT) discussion, a repeat resection
was performed and no evidence of residual tumour was
demonstrated histologically. No patients received any
additional post-operative radiotherapy.
Toronto Extremity Salvage Scores (TESS) were obtained
for 16 of 17 patients following treatment (Table 3). TESS
improved over time in all cases, either due to an expected
increase in score as follow-up progressed, due to recovery
of a radial nerve neuropraxia with one patient (from 47 to
97.2), or after reconstructive surgery following tumour re-
section for two patients.
Sixteen patients remain under active follow-up, as one
patient died with myxofibrosarcoma of the forearm died
after an unrelated small bowel perforation. After a me-
dian follow-up of 27 months (range 19 to 59 months),
no local recurrences have been diagnosed. One patient
developed metastatic lymphadenopathy of the axilla
treated with resection (now disease free), and one pa-
tient has developed pulmonary metastatic disease being
treated palliatively.
Discussion
Our study shows that the use of three-dimensional con-
formal radiotherapy given between 6 and 8 weeks prior
to surgery is associated with a wound complication rate
of 17.6% which is comparable to the level of wound
complication documented for post-operative, or adju-
vant, radiotherapy. Patients in our study were treated for
tumours in anatomically challenging areas which would
be assumed to have a high rate of complications. We
have demonstrated that excellent functional outcome
can be obtained for periarticular soft tissue sarcomasication post-operatively, all of which were treated
mplication Management Duration
hiscence part of SSG Secondary intention, antibiotics 5 weeks
ound dehiscence Secondary intention, antibiotics 4 months
perficial infection Oral augmentin 1 week
Table 2 Necrosis of 50% to 100% was demonstrated in 10 of 11 tumours in which it was possible to make an accurate
assessment
Gender Age Diagnosis Site of tumour Staging Minimum margin Margin Necrosis
M 48 Myxoid liposarcoma Right knee T2bN0M0 1 mm Negative 100%
F 41 Myxoid liposarcoma Left leg ant/lat T2bN0M0 0.5 mm Negative
M 83 Myxofibrosarcoma Right forearm/wrist T1aN0M0 2 mm Negative 98%
F 57 Malignant fibrous tumour Right popliteal fossa T2bN0M0 1 mm Negative
F 42 Myxoid liposarcoma Right popliteal fossa T2bN0M0 >5 mm Negative 95%
M 57 Extraskeletal myxoid chondrosarcoma Left wrist/forearm T1bN0M0 0.5 mm Negative
M 54 Myxoid liposarcoma Left calf/ankle T2bN0M0 2 mm Negative 100%
M 31 Sclerosing epithelioid fibrosarcoma Left medial knee/thigh T2bN0M0 1 mm Negative
M 59 Extraskeletal myxoid chondrosarcoma Left knee T2bN0M0 0.5 mm Negative
M 50 Synovial sarcoma Left thigh/knee T2bN0M0 0 mm Positive 75%
M 31 Pleomorphic liposarcoma Left anterior thigh/knee T2bN0M0 3 mm Negative 0%
F 77 Spindle cell sarcoma Left wrist/forearm T2bN0M0 3 mm Negative 99%
F 37 Leiomyosarcoma Right triceps/elbow T2bN0M0 0.5 mm Negative 50%
M 46 Myxoid liposarcoma Left posterior knee/thigh T2bN0M0 1 mm Negative 100%
M 54 Pleomorphic myxofibrosarcoma Right elbow T2bN0M0 >5 mm Negative 100%
F 75 Pleomorphic sarcoma Left lateral shoulder T2bN0M0 >3 mm Negative 50%
F 51 Myxoid liposarcoma Right posteromedial thigh T2bN0M0 1 mm Negative
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limb salvage surgery.
The use of neo-adjuvant versus adjuvant radiotherapy
is a controversial issue in the management of STS [3].
Although increased wound complications with the use
of neo-adjuvant radiotherapy are documented in the lit-
erature, benefits include better long-term function and
potentially patient survival rates [4,6,7,9].
Our study shows that three patients (17.6%) developed
a wound complication and none required operative
management. One patient was treated with a week-long
course of oral antibiotics to treat a minor infection after
resection of a tumour overlying the wrist. One patient
developed a minor infection and dehiscence of a small
area of a split skin graft following resection of a myxofi-
brosarcoma overlying the right wrist and was treated
with a 1-week course of antibiotics and 5 weeks of
supervised dressings. One wound complication was clas-
sified as major due to protracted conservative manage-
ment, which took 4 months to heal: this patient had
excision of a myxoid liposarcoma overlying the left
ankle. The surgical wound appeared to be healingTable 3 Toronto Extremity Salvage Scores (TESS) were obtain
Mean TESS
1st score Time from op
Upper limb 86.1 (47 to 100) 13.4 months (7 to
Lower limb 77.2 (39.5 to 99.2) 18.3 months (3 to
Total 80.9 16.7 monthsinitially but then broke down between day 14 to 21 post-
surgery and dehisced. The wound required treatment
with a negative pressure dressing (VAC) and a two of
courses of oral antibiotics. No inpatient or operative
treatment was undertaken.
O’Sullivan et al. and Cannon et al. show a higher
wound complication rate in patients treated with neo-
adjuvant radiotherapy [6,10]. O’Sullivan et al.’s land
mark paper (2002) randomised patients to neo-adjuvant
or adjuvant radiotherapy with the primary end point of a
wound complication (infection or repeat procedure)
within 120 days of surgery. Of 88 patients, 31 (35%) in
the neo-adjuvant group compared to 16 of 94 patients
(17%) in the adjuvant group suffered a wound complica-
tion, with lower limb tumours of both groups being
most common. Wound complication rates from a study
by Cannon et al. were similar (34% neo-adjuvant vs. 16%
adjuvant) [10]. There was a higher proportion of patients
with tumours of the thigh in these studies compared to
our own, in which a higher complication rate was noted
when compared to other anatomical sites (45% neo-
adjuvant and 28% adjuvant) [6]. However, in O’Sullivaned for 16 of 17 patients following treatment
2nd score Time from op
29) 98.5 (97.5 to 100) 23.4 months (17 to 39)
44) 85.5 (53.1 to 100) 28.3 months (13 to 54)
89.1 26.7 months
Green et al. World Journal of Surgical Oncology  (2015) 13:108 Page 5 of 6et al.’s study, patients received surgery between 3 and
6 weeks following completion of neo-adjuvant radiother-
apy, with a 5-cm margin proximal and distal to the
tumour included in the radiation field [6]. We scheduled
patients for surgery 6 to 8 weeks after completion of three-
dimensional conformal radiotherapy and margin of 2 to
3 cm, with none of our patients receiving a post-operative
boost of radiotherapy. Baldini et al. demonstrated that flap
closure or SSG is associated with increased risk of wound
complication; primary closure of the wound was achieved
for 15 of 17 patients (88.2%) in our study, compared to 58
of 88 (66%) in O’Sullivan et al.’s paper and 206 of 269 pa-
tients (77%) in Cannon et al.’s study [6,10,16]. Finally, we
delivered radiotherapy in the modality of three-dimensional
conformal radiotherapy, which was not performed in these
previous studies. These factors may explain the improved
wound complication rate in our series.
This study describes a set protocol of management for
periarticular STS, based on neo-adjuvant radiotherapy
and limb salvage surgery, performed in a single centre.
There are very few articles in the literature describing
the treatment of patients with a soft tissue sarcoma close
to an articulation. Turcotte et al. Rudiger et al. and
Pritsch et al. all described small groups of patients
treated for STS of the popliteal fossa with most receiving
limb salvage surgery [13-15], but treatment was varied
and it is therefore difficult to assess the results of these
papers in detail. Wound complication rates therefore
vary; Pritsch et al. quotes a total wound complication
rate of 23.1% (6 of 26 patients) with two patients requir-
ing surgical debridement, and Rudiger et al. quotes a
radiotherapy-related wound complication rate of 26.7%
(4 of 15 patients). However, with both studies, it is unclear
which patients received neo-adjuvant or adjuvant radio-
therapy. Our paper therefore improves the literature with
regard to the management of periarticular STS.
Other parameters of success of treatment include clear-
ance of tumour, local control and long-term function. A
reduction of mean maximal diameter of tumour in this
group of patients was demonstrated, which has been
noted in previous studies involving STS and in particular
myxoid liposarcoma [17,18]. Following neo-adjuvant
radiotherapy, 16 of 17 patients (94.1%) had clear margins
on histological analysis. Zagars et al. also demonstrated
that patients treated with neo-adjuvant radiotherapy
showed a lower rate of positive surgical margins (86% vs.
67%) and post-radiotherapy complications [9].
With regard to function, three patients initially re-
corded low TESS; one patient was only 3 months after
surgery, one patient suffered a transient wrist drop and
one patient required excision of their quadriceps tendon.
Two of these patients have made a significant improve-
ment during their post-operative recovery, with a mild
improvement noted for the third patient. However, withmean TESS scores for upper limb and lower limb tu-
mours being 98.5 (mean 23.4 months) and 85.5 (mean
28.3 months), respectively, excellent functional outcomes
have been obtained.
Although these results presented are promising, this
study is not without limitation. The sample size is small,
and hence, it is difficult to assess whether age, gender,
tumour site and grade affect patient function, local re-
currence and survival. Eleven of our 17 patients had an
MRI scan between completion of radiotherapy and prior
to surgery; this was highlighted within the department
on completion of this study, and it is now standard prac-
tice in our unit to repeat the MRI scan after completion
of radiotherapy. A limitation of the study is the absence
of a control group of patients with periarticular tumours
managed with surgery and adjuvant radiotherapy. The
aim of this study was not to compare radiotherapy in ad-
juvant and neo-adjuvant settings as large studies have
done this. The intention was to demonstrate that the
wound complication rate with this technique is lower
than previous studies of neo-adjuvant radiotherapy have
reported. An acceptable wound complication rate allows
this technique, with the associated benefits of reduced
radiotherapy dosage, to be more widely adopted. Al-
though the primary end point for this study was the rate
of wound complication, follow-up continues and this
will identify the local control rate.
Further studies are required with regard to delivery of
radiotherapy. The VORTEX trial, a prospective rando-
mised trial comparing the use of large, extended radiother-
apy volumes with a smaller radiotherapy volume for
adjuvant radiotherapy [5] has recently closed. The aim of
this national UK trial is to assess if smaller volumes of
radiotherapy affect functional outcome without comprom-
ising on local recurrence or patient survival. Results from
this study may inform a future trial involving the use of
neo-adjuvant radiotherapy.
Conclusions
In conclusion, the primary outcome measure, wound com-
plication rate, was better than the rate previously identified
in the literature. If equivalent wound complication rate,
local control and patient survival can be achieved with a
lower radiation dose compared to adjuvant radiotherapy,
this should confer a benefit to the patient.
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